Skin Cancer Home > DTIC-Dome and Breastfeeding
The manufacturer of DTIC-Dome (dacarbazine) recommends that women not breastfeed while undergoing treatment with this chemotherapy drug. Although no studies have been done to determine whether this drug passes through breast milk or if it would harm a nursing infant, the drug is associated with potentially dangerous side effects, which may pose a risk to a baby whose mother takes it while breastfeeding.
At this time, it is unknown if DTIC-Dome® (dacarbazine) passes through breast milk in humans. The manufacturer of the drug recommends that women not breastfeed during treatment. Therefore, if you are breastfeeding or plan to start, talk to your healthcare provider before using this medication.
DTIC-Dome has not been studied in breastfeeding women. Therefore, it is unknown if the medication passes through breast milk, or if it would harm a nursing child.
While the lack of information is certainly frustrating, it is important to understand that studies of medications are rarely done in women who are nursing, as doing so would usually expose an infant, who will not directly benefit from the medication, to possible risks from the medication.
Many medicines pass through breast milk to some extent. Because of the potential risks associated with using DTIC-Dome, such as low blood cell counts and the possible risk of developing other tumors, the manufacturer of the drug recommends that women should not breastfeed during DTIC-Dome treatment.
If your healthcare provider recommends breastfeeding during DTIC-Dome treatment, let your child's healthcare provider know if you notice any possible side effects in your child. Some of the potential side effects may include:
- Nausea and vomiting
- Signs of infection, such as fever
- Unusual or excessive crying
- Reduced appetite
- Extreme drowsiness
- Any unusual bleeding or bruising
- Anything else that just doesn't seem right.